Soleus Capital Management L.P. Raises Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Soleus Capital Management L.P. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 5.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,681,242 shares of the biopharmaceutical company’s stock after purchasing an additional 146,702 shares during the period. TG Therapeutics makes up approximately 5.1% of Soleus Capital Management L.P.’s investment portfolio, making the stock its 3rd biggest holding. Soleus Capital Management L.P.’s holdings in TG Therapeutics were worth $80,705,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $245,000. Castellan Group purchased a new stake in TG Therapeutics in the fourth quarter worth $8,539,000. Barclays PLC lifted its position in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. Stratos Wealth Advisors LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter valued at $241,000. Finally, Strategic Financial Concepts LLC bought a new position in shares of TG Therapeutics in the fourth quarter worth about $1,404,000. Institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

TGTX has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Stock Performance

TGTX stock opened at $34.36 on Monday. TG Therapeutics, Inc. has a 1-year low of $15.16 and a 1-year high of $46.48. The business has a 50-day moving average price of $38.59 and a 200 day moving average price of $34.03. The company has a market capitalization of $5.45 billion, a P/E ratio of -343.57 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the prior year, the firm posted ($0.07) EPS. The company’s revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.